Comparison 2. PDS: LVRD (> 1 cm) versus NMRD.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
2.1 Overall survival	14		Hazard Ratio (IV, Random, 95% CI)	2.50 [2.13, 2.94]
2.1.1 Advanced stage (III/IV)	8		Hazard Ratio (IV, Random, 95% CI)	2.44 [1.90, 3.14]
2.1.2 Stage III	1		Hazard Ratio (IV, Random, 95% CI)	2.47 [2.09, 2.92]
2.1.3 Stage IIIC	3		Hazard Ratio (IV, Random, 95% CI)	3.27 [2.42, 4.42]
2.1.4 Stage IV	2		Hazard Ratio (IV, Random, 95% CI)	2.16 [1.57, 2.96]
2.2 Overall survival ‐ sensitivity analysis using fixed effects model	14		Hazard Ratio (IV, Fixed, 95% CI)	2.27 [2.09, 2.48]
2.2.1 Advanced stage (III/IV)	8		Hazard Ratio (IV, Fixed, 95% CI)	2.10 [1.87, 2.35]
2.2.2 Stage III	1		Hazard Ratio (IV, Fixed, 95% CI)	2.47 [2.09, 2.92]
2.2.3 Stage IIIC	3		Hazard Ratio (IV, Fixed, 95% CI)	3.27 [2.42, 4.42]
2.2.4 Stage IV	2		Hazard Ratio (IV, Fixed, 95% CI)	2.16 [1.57, 2.96]
2.3 Overall survival ‐ sensitivity analysis excluding Melamed 2017b and Winter 2007	12		Hazard Ratio (IV, Random, 95% CI)	2.65 [2.20, 3.19]
2.3.1 Advanced stage (III/IV)	7		Hazard Ratio (IV, Random, 95% CI)	2.63 [1.99, 3.47]
2.3.2 Stage IIIC	3		Hazard Ratio (IV, Random, 95% CI)	3.27 [2.42, 4.42]
2.3.3 Stage IV	2		Hazard Ratio (IV, Random, 95% CI)	2.16 [1.57, 2.96]
2.4 Progression‐free survival	6		Hazard Ratio (IV, Random, 95% CI)	2.10 [1.84, 2.40]
2.4.1 Advanced stage (III/IV)	3		Hazard Ratio (IV, Random, 95% CI)	1.92 [1.62, 2.27]
2.4.2 Stage III	1		Hazard Ratio (IV, Random, 95% CI)	2.36 [2.04, 2.73]
2.4.3 Stage IIIC	1		Hazard Ratio (IV, Random, 95% CI)	2.56 [1.54, 4.26]
2.4.4 Stage IV	1		Hazard Ratio (IV, Random, 95% CI)	1.82 [1.28, 2.59]